Trial Profile
Pilot study to evaluate glycemic control with GlucoTab using an ultra-long acting insulin analogue in non-critically ill patients with type 2 diabetes at the general ward
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jun 2020
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary) ; Insulin glulisine (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms GlucoTab_U300
- 20 Dec 2017 New trial record